The Use of an Inhaled Salt Solution to Treat Viral Lung Infections in Infants.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00151905
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : May 7, 2007
Information provided by:
Sheikh Khalifa Medical City

September 7, 2005
September 9, 2005
May 7, 2007
November 2003
Not Provided
Length of stay.
Same as current
Complete list of historical versions of study NCT00151905 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The Use of an Inhaled Salt Solution to Treat Viral Lung Infections in Infants.
Nebulized Hypertonic Saline in the Treatment of Bronchiolitis in Infants
Bronchiolitis is a common viral lung infection in infants. Standard treatment often includes the use of inhaled medications which are usually first mixed with a standard salt solution. Inhalation of a more concentrated salt solution (hypertonic saline) has been successfully used to treat other types of lung disease in children and adults. The purpose of this study is to see if using inhaled hypertonic saline helps infants with bronchiolitis get better more quickly.

Bronchiolitis is a common illness in infants and is associated with a significant morbidity. Standard therapy is controversial and largely ineffective; care is mostly supportive although nebulized medications continue to be commonly used. These medications are typically mixed with normal saline to produce a sufficient volume for efficient nebulization.

Inhaled hypertonic saline has been used to aid airway clearance in children with cystic fibrosis. It has also been used, in low dose, in two small studies in children with bronchiolitis. The current study is a randomized, double-blind, placebo-controlled, multi-center trial comparing frequent dosing with 3% hypertonic saline compared to normal saline in the treatment of infants hospitalized with bronchiolitis.

Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Drug: 3 % hypertonic saline
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
September 2006
Not Provided

Inclusion Criteria:

  • Corrected age maximum 18 months, plus
  • History of preceding viral upper respiratory tract infection, plus
  • Presence of wheezing and/or crackles on auscultation, plus
  • Respiratory Distress Assessment Instrument (RDAI) score of 4 or greater, or oxygen saturation of 93% or less in room air, plus
  • Admitted to hospital

Exclusion Criteria:

  • Prior history of wheezing, or
  • History of chronic cardiopulmonary disease or immunodeficiency, or
  • Critical illness at presentation requiring admission to ICU, or
  • Use of nebulized hypertonic saline within previous 12 hours, or
  • Prematurity (gestational age 34 weeks or less).
Sexes Eligible for Study: All
up to 18 Months   (Child)
Contact information is only displayed when the study is recruiting subjects
Canada,   United Arab Emirates
Not Provided
Not Provided
Not Provided
Not Provided
Sheikh Khalifa Medical City
Not Provided
Principal Investigator: Brian A Kuzik, MD, FRCP Sheikh Khalifa Medical City
Sheikh Khalifa Medical City
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP